Research Article

Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR-23b-3p/MRC2 Axis

Xu Yang1,2, Guixia Wu3, Fan Yang4, Lang He5, Xiaohui Xie6, Lan Li1, Lei Yang1, Yulan Ma1, Qian Zhang1, Jiao Chen1, SiYing Zou1, Qian Han1, Yan Wang7, Shuai Liu1, Juan Li1, Bin Han1, and KaiJiang Liu2

1Department of Obstetrics and Gynecology, The Fifth Affiliated People’s Hospital of Chengdu University of Traditional Chinese Medicine, No. 33, Mashi Street, Wenjiang District, Chengdu 610000, China
2Department of Gynecological Oncology, Ren Ji Hospital, School of Medicine, Shanghai JiaoTong University, No. 145 Middle Shandong Road, Huangpu District, Shanghai 200001, China
3Department of Physiology, School of Basic Medicine, Xinjiang Medical University, China
4Department of Pathology, The Fifth Affiliated People’s Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
5Department of Oncology, The Fifth Affiliated People’s Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
6Department of Gynecology and Obstetrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
7Department of Laboratory, The Fifth Affiliated People’s Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Correspondence should be addressed to Xu Yang; zhizihuakai@cdutcm.edu.cn and KaiJiang Liu; liukaijiang@263.net

Received 12 January 2021; Revised 11 April 2021; Accepted 5 June 2021; Published 21 July 2021

Academic Editor: Jayeeta Ghose

Copyright © 2021 Xu Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ovarian cancer (OC), the third common gynecologic malignancy, contributes to the most cancer-caused mortality in women. However, 70% of patients with OC are diagnosed at an advanced stage, of which the 5-year survival is less than 30%. Long noncoding RNAs (long ncRNAs or lncRNA), a type of RNA with exceeding 200 nucleotides in length but no protein-coding capability, have been demonstrated to involve the pathogenesis of various cancers and show considerable potential in the diagnosis of OC. In this study, we found that the LINC00909 expression in tumor and serum specimens of OC patients was elevated, determined by real-time quantitative, and droplet digital PCR. In receiver operating characteristic (ROC) analysis, our results revealed that serum LINC00909 distinguished cancers from normal ovarian tissue with 87.8% of sensitivity and 69.6% of specificity (AUC, 81.2%) and distinguished serous ovarian cancer from normal ovarian tissue with 90.0% of sensitivity and 75.9% of specificity (AUC, 84.5%). Furthermore, we observed that the tumor and serum LINC00909 level was positively associated with the International Federation of Gynecology and Obstetrics (FIGO) stage and the Eastern Cooperative Oncology Group (ECOG) score (reflecting patients’ performance status). Also, patients with low serum LINC00909 level showed a longer overall (hazard ratio, HR = 1.874, p = 0.0004) and progression-free (HR = 1.656, p = 0.0017) survival. Functional assays indicated that the elevation of LINC00909 expression contributes to cell proliferation, migration, and invasion capability of ovarian cancer cells. Besides, we demonstrated that LINC00909 functions as a competing endogenous RNA (ceRNA) of MRC2 mRNA by sponging miR-23-3p, and thereby promotes epithelial-to-mesenchymal transition (EMT) of ovarian cancer cells. Therefore, we highlight that the LINC00909/miR-23b-3p/MRC2 axis is implicated in the pathogenesis of ovarian cancer, and serum LINC00909 may be a promising biomarker for the diagnosis of OC.
1. Introduction

Ovarian cancer (OC), the third common gynecologic malignancy, contributes to the most cancer-caused mortality in women and increases with approximately 22,000 new cases and 14,180 deaths every year in the United States [1, 2]. In histological subtypes, approximately 90% of OC is epithelial ovarian cancer, which consists of serous, endometrioid, and clear-cell ovarian carcinoma [2–4]. In the examination, the early-stage OC, such as the International Federation of Gynecology and Obstetrics (FIGO) stage-I/II, is difficult to diagnose because most symptoms of OC are nonspecific. For example, symptoms of early OC may appear similar to irritable bowel syndrome [5]. Due to the lack of early detection or screening test, about 70% of patients with OC are diagnosed at an advanced stage (FIGO stage III/IV), a mere 30% of which are expected to survive 5 years [1, 6, 7]. In contrast, the 5-year overall survival of patients with early-stage OC was reported to be 70-95% [3, 4]. Therefore, it is definitely beneficial to reducing OC-caused mortality to develop more effective diagnostic methods for this disease.

Long noncoding RNAs (long ncRNAs or lncRNAs) are a type of RNA with lengths exceeding 200 nucleotides but have no protein-coding capability [8–13]. Based on their genomic location, lncRNAs are categorized as intergenic, intronic, divergent, and antisense subtypes, especially the long intervening/intergenic noncoding RNAs (lincRNAs) [10, 14–20]. In functions, convincing studies by independent groups have shown that lncRNAs are implicated in a variety of cancers (such as cervical, bladder, colon, lung, glioblastoma, hematopoietic, and prostate) by influencing cell proliferation, differentiation, apoptosis, etc. [12, 13, 21–27]. By analyzing the OC transcriptome datasets from TCGA, Liang et al. found that PTAR, a lncRNA, was significantly upregulated in the mesenchymal subtype samples compared with the epithelial subtype samples [28]. In 2017, Wu et al. demonstrated that ABHD11-AS1 expression in epithelial ovarian cancer tissues was higher than that in normal ovarian tissue and was positively associated with the tumor stage (stage I/II vs. stage III/IV) [29]. Moreover, Wang et al. proved that, compared with cisplatin-sensitive ovarian cancer tissues and cells, PANDAR exhibits higher expression in cisplatin-resistant ovarian ones, and loss-function of PANDAR causes a significant tumor growth arrest [22]. Accordingly, lncRNAs exhibit a huge potential in the clinical application of OC diagnoses, such as tumor grading and chemosensitivity detection.

In this study, by reanalyzing the published OC transcriptome microarray dataset in GEO, we found an upregulated lncRNA, LINC00909, both in low- and high-grade serous ovarian cancers. This finding was further validated in tumor and serum specimens of 217 OC patients by comparing them with 89 normal ovarian tissues. Moreover, we comprehensively evaluated the advantages of the tumor and serum LINC00909 in possible clinical applications including tumor diagnosis and grading and prognosis prediction. In a mechanism, we demonstrated that the elevated LINC00909 level in ovarian cancer cells upregulates the expression of MRC2 by sponging miR-23b-3p and thereby promotes cell proliferation, migration, invasion, and EMT of ovarian cancer cells.

2. Methods and Materials

2.1. Patients. In the present study, a total of 89 normal participants and 217 patients with histologically validated primary ovarian cancer were enrolled in The Fifth Affiliated People’s Hospital of Chengdu University of Traditional Chinese Medicine from Jan 2014 to Apr 2019. The specimens of primary ovarian cancer and the related blood were collected and stored at -80°C for a long time. The tumor sections of each patient were checked by 3 oncologists. The clinical manifestations of patients are presented in Table 1. All the tumors were graded by 3 independent pathologists using the International Federation of Gynecology and Obstetrics (FIGO) grading system (good to bad: I-IV) [5]. The performance status of patients was assessed by oncology healthcare professionals using the Eastern Cooperative Oncology Group (ECOG) score (good to bad: 0-5) [30]. All participants or their families signed the written informed consent. The methodologies involved in this study conformed to the Declaration of Helsinki. The protocols used in the present study also were approved by the ethics committee of Chengdu University of Traditional Chinese Medicine.

2.2. RNA Extraction. Tumor tissues were immediately immersed into RNAlater RNA Stabilization Reagent from Thermo Fisher Scientific (Cat: AM7021, Waltham, USA) at 4°C for 24 hrs and then stored at -80°C for a long time. Blood samples in a vacuum collection tube were incubated in 37°C water bath for more than 30 min to completely coagulate. Then, the blood samples were centrifugated for 10 min at 1500 g (room temperature) to obtain cell-free serum fraction, which was immediately frozen at -80°C for further use. The RNA of tumor tissues was extracted by RNeasy Protect Mini Kit from Qiagen (Cat: 74124, Germantown, MD, USA), and serum RNA by QIAamp UltraSens Virus Kit from Qiagen (Cat: 53704, Germantown, MD, USA), following the manufacturer’s instruction.

2.3. Real-Time Quantitative and Droplet Digital PCR. For the quantification of tumor tissue RNA, real-time qPCR was performed on 7500 Real-Time PCR systems (Applied Biosystems, Waltham, USA) using TB Green Fast qPCR Mix from TaKaRa (Cat: RR430A, Beijing, China). The relative level of targets was analyzed by the ΔΔCt method using GAPDH mRNA as the internal control. In the case of serum RNA, droplet digital PCR was carried out for absolute quantification using droplet digital polymerase chain reaction (ddPCR) Supermix on a BioRad QX200 Droplet Digital PCR System (Munich, Germany) following the manufacturer’s instruction. Briefly, 20 μl PCR was mixed with 70 μl droplet generator oil pipetted into the cavities of the droplet generator cartridges (Bio-Rad) to generate droplet, and then, 40 μl droplet suspension was transferred into 200 μl PCR tubes. After a brief spin down, the tubes were located into the PCR machine to perform the program of 95°C for 10 min followed by 41 × 95°C for 30 s and 60°C for 60 s and 98°C
Table 1: Characteristics of patients with ovarian cancers.

| Characteristics | Number (N = 217) |
|-----------------|------------------|
| Age (Median)    | 67 years (range 21-90 years) |
| FIGO stage     |                  |
| I               | 31 (14.3%)       |
| II              | 33 (15.2%)       |
| III             | 80 (36.9%)       |
| IV              | 71 (32.7%)       |
| ECOG            |                  |
| 0               | 35 (16.1%)       |
| I               | 54 (24.9%)       |
| II              | 51 (23.5%)       |
| III             | 69 (31.8%)       |
| IV              | 7 (3.2%)         |
| Histologic subtypes |                |
| Serous          | 170 (78.3%)      |
| Endometriads    | 25 (11.5%)       |
| Clear cell      | 21 (9.7%)        |
| Recurrence      |                  |
| PFS             | Median (479 days) with range of 53-1362 days |
| NO relapse      | 76 (35%)         |
| Relapse         | 140 (64.5%)      |
| Survival        |                  |
| OS              | Median (618 days) with range of 102-1774 days |
| Alive           | 172 (79.3%)      |
| Dead            | 45 (20.7%)       |

FIGO stage (I-IV), FIGO Committee on Gynecologic Oncology 2009: I: tumor confined to ovaries or fallopian tube(s); II: tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer (Tp); III: tumor involves one or both ovaries, or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes; IV: distant metastasis excluding peritoneal metastases. ECOG (0-IV), Eastern Cooperative Oncology Group score 0: fully active, able to carry on all predisease performance without restriction; I: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework and office work; II: ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours; III: capable of only limited self-care, confined to bed or chair more than 50% of waking hours; IV: completely disabled; cannot carry out any self-care; totally confined to bed or chair; V: dead. PFS: progression-free survival, OV: overall survival.

for 10 min. The level of each target was detected using a QX200 droplet reader, and the data analysis was analyzed using the QUANTALIFE (Bio-Rad) software. All the involved primers for PCR were listed in Table 2.

2.4. Cell Culture. SKOV3 (Cat: HTB-7) cells were purchased from American Type Culture Collection (ATCC) and cultured in ATCC-formulated McCoy’s 5a Medium Modified (Cat: 30-2007) plus 10% fetal bovine serum (FBS, Gibco, Rockville, USA) and 50 μg/ml penicillin/streptomycin (P/S, Gibco, Rockville, USA). CAOV4 (Cat: HTB-76) cells also were purchased from ATCC but cultured in ATCC-formulated Leibovitz’s L-15 Medium (Cat: 30-2008) plus 10% FBS and 50 μg/ml P/S. A2780 (Cat: 93112519) cells were purchased from the European Collection of Authenticated Cell Cultures (ECACC) and cultured in RPMI-1640 plus 2 mM Glutamine, 10% FBS, and 50 μg/ml P/S. JHOS4 (Cat: RCB1678) cells were purchased from cell bank of RIKEN BioResource Research Center and cultured in DMEM/HamF12 plus 0.1 mM NEAA, 10% FBS, and 50 μg/ml P/S. EFO21 (Cat: ACC235) was purchased from DSMZ-German Collection of Microorganisms and Cell Cultures and cultured in RPMI-1640 plus 10% FBS, 50 μg/ml P/S, 2 mM glutamine, 1 × MEM nonessential amino acids, and 1 mM sodium pyruvate. OVCAR4 cells were purchased from COBIOER Company (Nanjing, China) and cultured in RPMI-1640 supplemented with 10% FBS plus 50 μg/ml P/S. All the cells were maintained in a CO2 incubator (with inner 37°C).

2.5. Generation of Stable Cell Lines. For the generation of stable overexpression and knockdown SKOV3/OVCAR4 cell lines, we utilized pLVX (Cat: #125839, Addgene) and pLKO.1 (Cat: #8453, Addgene) lentivirus vector to deliver gene sequences, respectively, and psPAX2 (Cat: #12260, Addgene) auxiliary constructs for lentivirus packaging. Firstly, HEK 293T (1 × 106 cells) were cotransfected with the constructs mentioned above using PolyJet (SL100688, Signagen, USA). 8 hrs after transfection, the medium of 293T cells was refreshed with a complete culture medium containing 10% FBS plus 50 μg/ml P/S. 48 hrs later, the supernatants were collected for virus particle purification using Lentivirus Concentration Reagent (Cat: BW-V2001-03, Chuangwei biosciences, China). After the determination of virus titer, the virus particle and 10 μg/ml polybrene (Cat: TR-1003-G, Sigma, USA) were added to infect OVCAR4 and SKOV3 cells. 2 days after infection, cells were added with 2 μg/ml puromycin (Cat: A1113802, ThermoFisher Scientific, USA) for the selection of virus-infected cells. Before usage for further experiments, all the cell lines were subjected to real-time qPCR to determine the expression level of target genes. The shRNA sequences involved in the study were listed in Table 2.

2.6. MTT Assay. SKOV3/OVCAR4 cell lines (2 × 104 cells/ml) were subsequently seeded into a 96-well with an interval of 0.5 days. After the growth of 2-3 days, cells in each well were incubated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (20 μl). After incubation at 3°C for 4 hrs, cells were supplemented with 150 μl DMSO to dissolve the obtained crystal at room temperature for 15 min. Finally, the cell growth curve was determined by detecting optical density (OD) at a wavelength of 450 nm using a Multiskan SkyHigh analyzer (Thermo Fisher, USA).

2.7. Wound Healing Assay. SKOV3 and VOCAR4 cell lines were seeded in a 12-well plate (2.5 × 105 cells/well). The next day, the confluent cell monolayer was scratched to create an artificial wound using a 10 μl pipette tip. On day 1, 2, and 3...
| Gene symbols | For real-time qPCR Sequences |
|--------------|----------------------------|
| ADIPOQ-AS1   | GGATTCCCGGAAAGCCTCGG       |
|              | GAGATGGCACCCCGTGGACC       |
| AGBL5-AS1    | GGGCATATCGGCGGTGCGCC       |
|              | CACCCCGGACACCTAGACAT       |
| C14orf132    | GCCCAGAGACACCGAGTGCGC      |
|              | AAGTCTCCTGGTGGGAGGAGTC     |
| CPEB1-AS1    | CAAGGGAGCGGGTGTCTGGG       |
|              | CAGGCAGCTGGGACACCTAGG      |
| DDX11-AS1    | GGTTCTGGGAGATGACCAAATGG   |
|              | CCAATTTCATTAGGGAGACCTC     |
| ELF3-AS1     | CATCACCTGCTGAACTTCA        |
|              | AGGGCATGGAGCTGACACTTCA     |
| ELOA-AS1     | CAGCAAGACTGTCAGTGCCG       |
|              | AGGCCGAGTACAGAGGACAGC      |
| EMX2OS       | GCGGAGTATTTGAGTGAGTGGG     |
|              | GGGCAATGCGCTGCTCAGCC       |
| FAM87B       | GAAGGCGGCTCCTCCTGAGG       |
|              | CTGCAGGCGAGACACACACC       |
| FGD5-AS1     | CTTCCACTGCTCCTAGG          |
|              | CTTCCTAAGCCAAGCCACACTGG    |
| HCG23        | AGGGCCCTTCAACAAGGACAGC     |
|              | ACTTCTCATTGTTAGGGAGGCTG    |
| HHIP-AS1     | CTTTCCCCTGCCAGTCCGCTT     |
|              | CACATCTCGGGTTGTTAGCTG      |
| HOTAIR1M     | AGCCAAAGGCGGCTGCTGCG      |
|              | AGCTGTGAGTGGTGCTAGGCA      |
| HOXA-AS2     | CTTGCTGCAAAGCCTCACAGCG    |
|              | TTCTTCAAGCCAGGAGTGGCGG     |
| LIF-AS1      | GGCACAGGAGCTCGACACTTCA     |
|              | CTTCTGATCCCTGCGCCAGG       |
| LIN00028     | GTTCTCCCCACACCCAGCT        |
|              | GAGACCCAGTTGGCTACAGC       |
| LIN00037     | GGGGAGAAGCGAGCTGTCACCT     |
|              | AGGTGCAAAAGCTGAGCGC        |
| LIN000346    | AGTGAGCCAGCTGCTAGG         |
|              | AGTGGACAGTGGCACACCGC       |
| LIN000461    | TCCCAAGAAGGGAAGACCCAT      |
|              | CATTGGATTCTCCGAGCCAGG       |
| LIN000467    | TGGAGGACGCTCCTGTCGACCT     |
|              | AGGGATCGGAGGCGTCTAGC       |
| LIN000484    | GCTTCCAGGCTCAGTCAGG        |
|              | TAGGAAGATTGTTAGGGCTG       |
| LIN000515    | GTTGAACAGGCGACATGATG       |
|              | GCTGGAGAGTGGCACTACGGA      |
| LIN000852    | GGTAAAGGCTGCTGCTGGCG      |
|              | AGACAGAGTACCTAGGCA         |
| LIN000893    | CAGCCTGTGGCTCACAACATT      |
|              | GTGACACAGCTAAATGTCAGC      |
| LIN000908    | TCAGAGTAGGGGGCTTACAGC      |
|              | AGAAACTCCGAGTGCTAGC        |
| LIN000909    | GCCTGAAACAGATGGGGAGG       |
|              | CGAGCTTCTGCTCCCACTTCAG     |
| LIN000917    | TCTCAGGAGATCAGTGGCAGG      |
|              | GGGTTAGGGCCTTGAGACCC       |
| LIN000921    | GCTTTGAGAACCAATCAGTAGTGG  |
|              | TCCTCTACTATCTTCGACGAGC     |
| LIN000996    | GAAAGTGGAGGGAGAATGCGCC     |
|              | GTTCTTGGATTCTCTGACACTG     |
| LIN01039     | ACAGTGGGCCCCATTTGCTAGG     |
|              | TCAGAGATTGACCTACAGG        |
| LIN01088     | TGGATTTCCGGGAAAGACTCCTG    |
|              | GCCGATTGAGCAGAGTGGTCG      |
| LIN01140     | TTGTCCTCCATGGCTGCTGTG     |
|              | ATCTCGTGGAGTGACTACG        |
| LIN01197     | GTGCTAGGGTACCGTCTGTG       |
|              | CAGCTTGGATACCGCTCCAGC      |
| LIN01320     | AGCCGATACGATCTCCAGAGAG    |
|              | TACCTTCCGAGATTAGTACAGT     |
| LIN01354     | GCCGGAGAAGAGCTTGAGGACG     |
|              | TCTCAGGCAATTGGGAGGACCG     |
| LIN01365     | GCTTCTTGGCAAGACCTCCTCC    |
|              | GAATTAAGCCTTGGGCTTGGGC     |
| LIN01391     | GCGGATGAGCCACCCATTCTT     |
|              | CGCGCAGTGGCTGCTAGC         |
| LIN01563     | GAGGCAAGGCGGAGAATGCTT     |
|              | CCCTCTGACAGCTGACTTCAG     |
| LIN01626     | CTCCCAATCATCCAAGTGTG       |
|              | AGACTGAGTGATTCTAGGACCC     |
| LIN01638     | GCTCACTTCCCTTACTCCATG      |
|              | TGTGGACTTGGGCTTGGTGCAG     |
| LIN01881     | CAGTCCAGGATCAGGAGTGGCG     |
|              | GTGCACGTGGAGCTGTGAGC       |
| LIN02158     | ACACCTGGACGGGGTGCTG        |
|              | CAGCCGCTTGCAGCTTACCAG     |
| LIN02278     | GATGTATTACCACACACACTCCT    |
|              | TGGAGATTTAGCCTACCCAG       |
| LIN022432    | TCATGCGAGGAGAAAGCCTCC     |
|              | ATCAATGCGGTTGGGTAGGTCG     |
| LIN022502    | CTCACTGCTGCTACAGTTTTC    |
|              | CCTGGAATCCGAGAAGGCC        |
| LIN02609     | TAAGACACCTGGCGGAGCTCG      |
|              | TGGCCTGGCTGCTCCAGCAG       |
| LMF1-AS1     | CCCATCAGAGACTGCGTCTCT      |
|              | TCTGCAGGGAACACTCCTGCGG     |
| Gene symbols | Forward (5′ →3′) | Reverse (5′ →3′) |
|--------------|-----------------|-----------------|
| MCF2L-AS1    | CTCTCTGAGCTCTCCTCGCC | CTTGCTACATTGGCCAGGCTCT |
| MIR100HG     | CCCCTCCTCAGAACTGTCCTC | GTTCTAGTGGCAGAAGCTGCAC |
| MIR396HG     | TCCACCTGCTCCAGCCTCC | CTGGGGAGGAGGGGTCCTTC |
| MIR99AHG     | GGCACCATATAACAAATGAGCCTTC | CTTCACATTGGCAAGCTCCAG |
| MLIP-AS1     | GAGGCTGATGCTAATGCCCCT | ACTTGGAGATTGCGAGAGGCC |
| PCAT19       | GAGGCTCCTCCCTTCTCGG | CTGGCCACATTGGGAAGGAC |
| PCOLCE-AS1   | CCTCAAGAGCAGAGGCAGCAG | TGCCAGACGACAGGGAGAAG |
| PGM5-AS1     | CTGGTGGAATCTGGGGAGT | CCCAGACGGTTTACAGAGCAG |
| PROSER2-AS1  | CTGAGTTCAAGCGGTCTGGC | AGCAACAGCGCAAGGAGCAG |
| RBMS3-AS3    | CTCCACCCACACAAGGAGT | AAGGAGCTTGGACGGGACC |
| SEMA3B-AS1   | CACAGGTGAGTGGGGAGG | CTCCAGGCTCAGCATGCCC |
| SLC16A1-AS1  | TCTCTGAGGAGGTGAGGAG | CATGTCGGCAGTGGTGTG |
| SNAI3-AS1    | GATCCAGGGGCTTCTGCT | CCTGGTGTCACAGCTCAG |
| STAM-AS1     | CTGGTCCTCAGGAGAGGCTG | GGTTTGCTAGGAATCTCACTAGT |
| SVIL-AS1     | GAGGCTCCTCCCTCAGGCTT | GTCTAGCTGGAGCTTGAGG |
| TRAF3IP2-AS1 | CTCCACCCACACAAGGAGT | AAGGAGCTTGGACGGGACC |
| TTN-AS1      | AGACGGACTGGTCTAGGT | AAGAATCTGCAGAGGAGCAT |
| TUG1         | CATCTCCAAAGCCTGACAG | CTTAGGCTTGACACACAG |
| XIST         | ATGTCACAGGCTTGTGAGAC | ATTAGCTGGAGCTTGAGG |
| ZBTB20-AS5   | GAGGAAAGGAGAAGCTCTGCAG | GGAGCTTGGACGGGACCT |
| ZEB1-AS1     | GAAGGGAGGAGCCTGTTTCC | CCCAGGCTCAGCATGCC |
| MBDT1        | GACGAGTACCTCGTGTAGTG | GCGACAAGCTCGGACAAAG |
| STAR3NL      | TTGGGTCGATACAGGAGAAG | TGGGCAGACATGGACAGAAC |
| ZNF839       | GTACAGCGGCTTGTGAGAAC | CTGGGACTCTCTTGTGAGG |
| JARID2       | ACCAGCTCTAAAGGAGACAG | TGCTGGAGACTTGAGG |
| NRXN3        | ATGGTGGCTTATCTCTTAC | CCTGGTTTATGGAAGCTG |
| FAS          | TCTGGTTCTACCTGCTGTG | CTGCTGAGACTCTAGGTT |
| CALCRL       | TTACCGCGATACAGGAGAA | GTCAGACAGCTCACGAGAG |
| LASP1        | CGAGAAGAGAACCCACTGCAA | CTGCCACATCGGAAAGC |
| DEPDC1       | TTTGGTCTCTGGATACAGAAGG | TGGAGAATTTCCGATGAG |
| SS18L2       | ATCGGCTGTCTTGGGAGACTA | GACATGCAAGCTGTGAG |
| CREBBP       | CAACCCCCCAAAAGCGCAAACT | CCGCCTGAGAAGCTCCAG |
| MRC2         | CAGAGGAGGACTATGGGCTCT | CTGCTGATCTGGAGGTT |
| PIK3C2A      | AAATGGGACGATGAGTTGGC | GGTTGGTGCCTGGTGAG |
| ALAS1        | AGGACAGGGTGCCACTACCTG | TCCCTACGGCATTTCTT |
| ETV1         | TGCGAATTGCTGAGCTTCTT | CGAAGATCGGATAGTTTTAT |
| BTBD7        | AAGGAAGCTTCTCTTCAAGGC | GCCCCTACTCTGCTAGG |
| MAP3K9       | TACCCGATACAGGAGAAGA | CTTGGTTGGAACATCTCTAG |
| HOXA11       | TGCCAGGTGTACTTACTGCTG | GTGGGAGGAGATAGTTGAT |
| ISL1         | GCGCAGGCTTAACTCATTGTTGGA | GCTATGGGCTACAGACCT |

ShRNA sequences (5′-3′):

| LINC00909#1  | CCGGGAGGCTGCTGGGATTTTCTACCTCAGTAAATCCCTAGACAGCCTCTTTTTTGG |
| LINC00909#2  | AATTCGAAAAAGGGCTCCTGGGATTTTCTACAGTAAATCCCTAGACAGCCTCTTTTTTGG |
| LINC00909#3  | AATTCGAAAAAGGGCTCCTGGGATTTTCTACAGTAAATCCCTAGACAGCCTCTTTTTTGG |

Oxidative Medicine and Cellular Longevity
Table 2: Continued.

| Gene symbols | For real-time qPCR Sequences | Reverse (5′→3′) |
|--------------|-----------------------------|-----------------|
| LINC00909#4  | CCGGGACTCTGTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| LINC00909#5  | CCGGCCTGTCAAAAAGAGTTGTGTTGACTCTCGAGATAACTTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| MRC2#1       | CCGGCCTGTCAAAAAGAGTTGTGTTGACTCTCGAGATAACTTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| MRC2#2       | CCGCCAGGACCAGATCAGTAATATCTCGAGATACTCAGGTGTCCATTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| LASP1#1      | CCGGGAAATGGAAGCACGACAAAGAACTCGAGTCTGTCATTCATTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| LASP1#2      | CCGGGAAATGGAAGCACGACAAAGAACTCGAGTCTGTCATTCATTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| ZNF839#1     | CCGGGAAATGGAAGCACGACAAAGAACTCGAGTCTGTCATTCATTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |
| ZNF839#2     | CCGGGAAATGGAAGCACGACAAAGAACTCGAGTCTGTCATTCATTCCCATTCAGAGTCTTTTTT | AATTCTAAAAAGACTCTGTAATGGGAAGTTATCTCGAGATAACTTCCCATTCAGAGTCTTTTTT |

after the scratch, the wound width was recorded using an inverted microscope.

2.8. Transwell Assay. SKOV3 and VOCAR4 cell lines were seeded on the upper side of the Matrigel-coated transwell chamber with a cell density of 3×10^4 cells/well. The medium of the bottom side was supplied with 20% FBS. After the growth of 24 hrs, the cells of the bottom side were fixed using the 4% paraformaldehyde for 30 min and immediately followed by stained using crystal violet for 30 min. Finally, the migrated cells to the bottom were to be imaged using a microscope for cell number counting.

2.9. Western Blot. The total protein of SKOV3/OVCAR4 cells was extracted using radioimmunoprecipitation assay buffer (Beyotime, Cat: P0013C). After quantification of total protein concentration, each sample was separated by electrophoresis of 10% sodium dodecyl sulfate- (SDS-) polyacrylamide gel (Beyotime, Cat: P0013C) and then transferred to a nitrocellulose filter membrane (Whatman, Cat: 10600001). After blocking using 5% fat-free milk at room temperature for 1 hr, the membranes were probed using primary antibodies at 4°C overnight. The next day, the membranes were briefly washed with 1× Tris-buffered saline containing Tween-20 (TBST, Beyotime, Cat: ST677) for 3×5 min, followed by being incubated with secondary antibodies (1:5000) for 2 hrs at room temperature. Finally, the protein bands were visualized using High-sig ECL Western Blotting Substrate (Tanon, Cat: 180-501) following the manufacturer’s instructions. The protein bands were quantified using the software of ImageJ. Anti-MRC2 (Cat: ab70132) was purchased from Abcam, and E-cadherin (Cat: #14472), N-cadherin (Cat: #13116), and vimentin (Cat: #5741) from Cell Signaling Technology (CST).

2.10. Dual-Luciferase Reporter Assay. To prove the interaction between LINC00909 and its putative miRNA targets by ENCORE online tools [31] (Stable1), we performed a dual-luciferase reporter assay using the LINC00909 Firefly luciferase construct as in Figure 1(a) and Renilla luciferase construct. Also, the direct interaction between miR-23b-3p and DEPDC1/MRC2/LASP1/ZNF839 mRNA was validated by dual-luciferase reporter assay using the LINC00909 Firefly luciferase constructs as shown in Figure 1(c).

12 hrs after transfection, 293T cells (0.2×10^6) were seeded into 12-well plates. The cells with 80% confluence were transiently cotransfected with Firefly (empty of sequence-specific), Renilla luciferase constructs, and miRNA-mimics or miRNA-NC (negative control). 48 hrs after transfection, cells were harvested for the luciferase activity determination using a Dual-Luciferase Assay kit (Promega, Cat: E1910) following the manufacturer’s protocol. The Firefly luciferase activities were normalized by Renilla luciferase. Each sample in the dual-luciferase reporter assay was assayed four times.

2.11. Data Mining. The published transcriptomic data of serous ovarian cancer (both high and low grade, 6 duplications for each group) and normal fallopian tube (control group, 6 duplications) from Gene Expression Omnibus (GEO, GSE135886) was used for exploring the roles of lncRNAs in OC diagnosis. The miRNA expression data were analyzed using the datasheet of GSM4797395 (GEO). We took advantage of R language packages including GEOquery, Limma, and UMAP for finding the differential expressed genes, in which p value < 0.01 and fold change > 2 were selected as the cutoff. The expression and subcellular location information of LINC00909 in cell lines were analyzed using database LncATLAS (https://lncatlas.crg.eu).
**Figure 1:** Continued.
2.12. Statistical Analysis. In this study, the software of GraphPad prism 7 (CA, USA) was used for statistical analysis. In the comparison of lncRNAs in each group, a nonparametric test based on the Kruskal–Wallis test was used, followed by Dunn’s multiple comparison correction. Receiver operating characteristic (ROC) curve analysis was carried out to estimate the diagnostic performance of lncRNAs using the pROC package. Spearman’s rank correlation test was carried out to evaluate the correlation between tumor and serum lncRNAs. Also, Kaplan–Meier analysis and the log-rank test were performed for progression-free survival (PFS) and overall survival (OS). For two-group comparison, student’s t-test or Mann–Whitney test (if the variances of samples are heterogeneous) was used; for comparison with more than three groups, one-way ANOVA followed by post hoc Tukey’s multiple comparisons was used. A p value < 0.05 was considered statistical significant (N.S, no significance; *p < 0.05, **p < 0.01, and ***p < 0.001).

3. Results

3.1. LncRNAs Are Differentially Expressed in OC Compared with Normal Ovarian Tissues. To explore the diagnostic significance of lncRNAs in the patients with primary ovarian cancer, we identified the differentially expressed genes (DEGs) in ovarian cancer (both low and high grade) compared with normal fallopian tube tissues using the published microarray data in the GEO database. We found 7102 differentially expressed probes in comparison to normal fallopian tube vs. low-grade ovarian cancer, as well as 7803 ones in comparison to normal fallopian tube vs. high-grade ovarian cancer (Figures 2(a) and 2(c)). In multidimensional scaling, the low- and high-grade groups show a close distance with each other (Figure 2(b)), suggesting there is considerable overlap in their differential expressed genes. Indeed, these two groups share 2723 differentially expressed probes (annotated as 2433 genes), including 2246 protein-coding genes, 37 lincRNAs, and 31 antisense transcripts.

Furthermore, the expression of all the identified differentially expressed lincRNAs was determined in 6 paired specimens of ovarian cancer and adjacent normal tissues by real-time qPCR. Fortunately, our results showed that lincRNAs levels, such as LINCO0893, LINCO0921, AGBL5-AS1, LIFAS1, EMX2OS, LINCO0909, ELOA-AS1, and LINCO00515, were significantly elevated in tumors, and in contrast, LINCO0917, LINCO0921, etc. were downregulated (Figures 2(d) and 2(e)).

3.2. LINCO0909 Expression Is Elevated in Tumors and Serum of OC Patients. Next, we further validated the identified lincRNAs in 89 normal ovarian tissues and 217 primary ovarian tumors (including 170 serous, 25 endometrioid, and 22 clear-cell ovarian cancers). Our results revealed that LINCO0909, ELOA-AS1, and LINCO00515 expressions were obviously increased in the tumors of serous, endometrioid, and clear-cell ovarian cancers when compared with that in
Figure 2: Continued.
Figure 2: LncRNAs are differentially expressed in OC compared with normal ovarian tissues. (a) Volcano and Meandiff plot of each two groups from the GSE135886 datasheet. Con.: normal fallopian tube tissue; low: low-grade primary ovarian cancer; high: high-grade primary ovarian cancer; fold change > 2 and p value < 0.01 serve as the cutoff. (b) Multidimensional scaling of three groups in (a). (c) Venn graph shows the overlap of differentially expressed probes between the indicated two groups. The groups are the same as in (a). (d, e) The level of lncRNAs was determined by real-time qPCR. 6 paired specimens of normal and ovarian cancer tissues were used for lncRNA relative quantification. N: normal tissues; T: tumor tissues.
Figure 3: Continued.
normal ovarian tissues (Figure 3(a) and S1A). Furthermore, we determined their level in the serum specimens using droplet digital PCR to facilitate the possible application in clinical diagnosis. Intriguingly, we observed that only the expression of LINC00909 in the endometrioid, clear-cell, and serous ovarian carcinoma were also substantially elevated when compared with normal ovarian tissues (Figure 3(b)).

Moreover, our findings showed that the expression of LINC00909 in the tumor was obviously associated with that in serum with an $R^2$ of 0.5604 ($p < 0.001$) (Figure 3(c)), implying that the elevation of serum LINC00909 may be the result of high LINC00909 expression in tumors. Altogether, we demonstrated that LINC00909 expression was upregulated in the tumor and serum of patients with ovarian cancer.

Furthermore, we carried out a receiver operating characteristic (ROC) analysis using tumor and serum LINC00909 level (median value as the cutoff) to evaluate their diagnostic performance for OC. Tumor LINC00909 distinguished cancers from normal ovarian tissue with 73.3% of sensitivity and 79.7% of specificity (AUC, 79.0%; 95% confidence interval (95% CI): 73.1%-85.0%) and distinguished serous ovarian cancer from normal ovarian tissue with 82.2% of sensitivity and 79.7% of specificity (AUC, 84.4%; 95% CI: 79.5%-89.3%) (Figure 3(d)). More interesting, serum LINC00909 showed a more considerable diagnostic performance in identifying ovarian cancer (sensitivity, 87.8%; specificity, 69.6%; and AUC, 81.2%) and serous ovarian cancer subtype (sensitivity, 90.0%; specificity, 75.9%; and AUC, 84.5%) from normal ovarian tissues (Figure 3(e)).

Besides, we observed that the tumor and serum LINC00909 in patients with advanced-stage OC were higher than that in FIGO stage I but not stage II (Fig. S1B). In the performance status of patients, our results showed that the ECOG score was positively associated with the tissue and serum LINC00909 level (Fig. S1C). The evidence suggests high LINC00909 level is an unfavorable indicator for patients with OC.

### 3.3 Serum LINC00909 Exhibits Considerable Diagnostic Performance for OC

We also tracked serum LINC00909 levels in follow-up samples ($n = 83$) collected at one-week postprimary surgery, one-week post the first cycle of platinum-based chemotherapy (CT), one-week post 3rd CT, and one-week post the end cycle of CT. We found that, after the primary surgery, the serum LINC00909 level of 43% of patients dramatically reduced to less than 0.5-fold of the initial level (Figures 4(a) and 4(b)). Moreover, the postoperation serum LINC00909 levels were further downregulated after the first and third cycles of CT (Figures 4(a) and 4(b)). However, after the last cycle of CT, the serum LINC00909 level failed to alter when compared with that after the 3rd CT (Figures 4(a) and 4(b)).

Besides, we performed overall and progression-free (PFS) survival analyses using both tissue and serum LINC00909 level (median expression value as the cutoff) of the primary diagnosis. As shown in Figure 4(c), low tissue and serum LINC00909 are favorable for the patients with ovarian cancers, with a hazard ratio of 1.643 (95% CI: 1.257-2.149, $p = 0.0021$) and 1.874 (95% CI: 1.433-2.450, $p = 0.0004$), respectively (Figure 4(c)). Likewise, the patients with low tissue or serum LINC00909 level had longer progression-free survivals with a hazard ratio of 1.471 (95% CI: 1.050-1.929, $p = 0.0033$) and 1.656 (95% CI: 1.022-2.223, $p = 0.0017$), respectively (Figure 4(d)). Altogether, a low (serum) LINC00909 level is favorable for patients with ovarian cancer.
Figure 4: Serum LINC00909 exhibits considerable diagnostic performance for OC. (a, b) The level of IncRNAs was determined by droplet digital PCR. 83 follow-up serum samples were collected at one-week postprimary surgery (postdiagnosis), one-week post the first cycle of platinum-based chemotherapy (1st CT), one-week post 3rd CT (3rd CT), and one-week post the end cycle of CT (post-CT) were used for IncRNA quantification. (c, d) LINC00909-based overall and progression-free survival analyses of OC. HR: hazard ratio. Log-rank (Mantel-Cox) test for statistical analysis.
Figure 5: Continued.
3.4. LINC00909 Functions as an Oncogenic Factor to Ovarian Cancer Cells.

To investigate the biological functions of LINC00909 in the tumorigenesis of ovarian cancer, we firstly detected its levels in 6 ovarian cancer cell lines, such as JHOS4, SKOV3, A2780, CAOV4, EFO21, and OVCAR4. Compared with tumor tissues, there was a higher LINC00909 level in JHOS4, SKOV3, and A2780, and in contrast, a lower expression in OVCAR4 (Fig. S2A). Therefore, we knocked down LINC00909 in SKOV3 using an shRNA vector and overexpressed it in OVCAR4 (Fig. S2B and C). Interestingly, knockdown of LINC00909 expression in SKOV3 cells significantly inhibited cell proliferation determined by MTT assay (Figure 5(a)), and in contrast, ectopic LINC00909 expression promoted cell growth of OVCAR4 cells (Fig. S2D). Consistently, we observed that knockdown of LINC00909 expression abated about 32.7% colony formation of SKOV3 cells (Figure 5(b)), and ectopic LINC00909 in OVCAR4 cells enhanced colony formation by 56.1% of the vector group (Fig. S2E). In soft agar assay, our results showed that LINC00909 contributed to cells’ anchorage-independent growth ability, indicated by the reduction in tumorsphere number in LINC00909-knockdown SKOV3 cells and the increased number in LINC00909-overexpressed OVCAR4 cells (Figure 5(c) and S2F).

In the wound-healing assay, we found that, after 3 days of growth, the scratch of LINC00909-knockdown SKOV3 cells was significantly wider than that of the scramble group (Figure 5(d)), suggesting cells’ migration is injured by loss-function of LINC00909. Meanwhile, our data also showed that overexpression of LINC00909 in OVCAR4 cells promoted the healing of scratch (Fig. S2G). Furthermore, we carried out a transwell assay using the cells mentioned above to evaluate their invasive ability. Our results revealed that knockdown of LINC00909 in SKOV3 cells restrained cell invasion, supported by the fewer cell numbers in two independent LINC00909-knockdown cell lines in the transwell.
Figure 6: Continued.
In another way, overexpression of LINC00909 in OVCAR4 cells remarkably enhanced cell invasion (Figure 5(e)). Besides, we observed that ectopic LINC00909 in OVCAR4 cells decreased E-cadherin and increased N-cadherin/vimentin expression, demonstrating that it promotes epithelial-to-mesenchymal transition (EMT) of ovarian cancer cells (Fig. S2H). In contrast, knock-down of LINC00909 expression partially reversed the process of EMT in SKOV3 cells (Figure 5(f)). Taken together, LINC00909 contributes to cell proliferation, colony formation, migration, invasion, and EMT of ovarian cancer cells in vitro.

3.5. miR-23b-3p Is a Critical Functional Mediator of LINC00909.

Currently, accumulating reports have indicated that lncRNAs, especially the cytoplasmic ones, involve the pathogenesis of various tumors by serving as competing endogenous RNAs (ceRNAs) to sponge functional miRNAs [32–34]. In the case of LINC00909, the expression and sub-cellular location data from cell lines showed that it mainly localizes in the cytoplasm (Fig. S3A), showing it is a potential ceRNA. Therefore, we analyzed the 33 putative miRNA interactors of LINC00909 from the STARBASE database (Table S1) and then verified their interaction using dual-luciferase reporter assay in 293T cells. Interestingly, we identified 14 miRNAs, such as miR-105-5p, miR-135b-5p, miR-23a/b, and miR-511-3p, those bound to LINC00909 (Figure 6(a)). In 461 miRNAs that are relatively highly expressed in ovarian cancer, we observed 4 validated LINC00909 binding miRNAs, including miR-23a/b-3p, miR-194-5p, and miR-874-3p (Figure 6(b)). Therefore, we hypothesized that LINC00909 achieves its biofunctions by sponging a certain one(s) of these four miRNAs. Next, we explored the functional roles of these 4 miRNAs in tumorigenesis using colony formation assay. Intriguingly, our results revealed that ectopic miR-23b-3p or miR-194-5p in SKOV3 cells significantly restrained colony formation (Figure 6(c) and S3B), indicating they are tumor suppressors in ovarian cancer in vitro. Besides, in miR-23b-3p but not miR-194-5p overexpressed OVCAR4 cells, ectopic LINC00909 still promotes colony formation (Figures 6(d) and 5(e)), suggesting that miR-23b-3p is the downstream functional mediator of LINC00909. Altogether, our results demonstrated that LINC00909 functions as an oncogene in ovarian cancer by sponging miR-23b-3p.

3.6. LINC00909 Functions as a ceRNA of MRC2, LASP1, and ZNF839 by Sponging miR-23b-3p.

To further investigate the mechanism that miR-23b-3p involves in the pathogenesis of ovarian cancer, we analyzed its targets using three different algorithms from miRcode, TargetScan, and mRDB databases, respectively. We finally identified 20 putative mRNA targets...
Figure 7: Continued.
Figure 7: LINC00909 achieves its biological functions in ovarian cancer via regulating MRC2. (a) Real-time qPCR revealed mRNA level of MRC2/ZNF839/DEPC1 in SKOV3 cells. In SKOV3 cells, MRC2/ZNF839/DEPC1 was stably knocked down, respectively, using shRNA vector. Scr: scramble. (b) Colony formation assay revealed the tumor characteristics of each SKOV3 cell line. Cells in (a) were used. (c) Real-time qPCR revealed mRNA level of MRC2/ZNF839/DEPC1 in OVCAR4 cells. In OVCAR4 cells, MRC2/ZNF839/DEPC1 was stably overexpressed, respectively. (d) Colony formation assay revealed the tumor characteristics of each OVCAR4 cell line. Cells in (c) were used. (e, f) Colony formation (e) and soft agar (f) assays revealed the tumor characteristics of each OVCAR4 cell line. Cells in S5A were used. (g) Western blot showed the protein level of EMT markers in OVCAR4 cells. Cells in Figure S5A were used. E-cadherin, epithelial marker; N-cadherin/vimentin, mesenchymal marker. (h) The working model of LINC00909 involves the pathogenesis of ovarian cancer cells.
of miR-23b-3p, including MBTD1, STARD3NL, and ZNF839 (Figure 1(a)). To validate if these miRNAs are really the targets of miR-23b-3p, we determined the alteration in their expression level when miR-23b-3p was overexpressed in SKOV3. Intriguingly, our real-time qPCR results showed that the expression of ZNF839, LASP1, DEPDC1, and MRC2 in mRNA level was obviously downregulated in miR-23b-3p overexpressed SKOV3 cells (Figure 1(b)). Consistently, the dual-luciferase reporter assay in 293T cells also indicated that miR-23b-3p directly interacted with the mRNA of these four genes (Figures 1(c) and 1(d)). These observations collectively imply that LINC00909 may function as a ceRNA of ZNF839, LASP1 DEPDC1, and MRC2 by sponging miR-23b-3p in ovarian cancer cells. Interestingly, we found that, in the ovarian cancer RNA expression datasheet from the GEPIA database, ZNF839, DEPDC1, and MRC2 were associated with LINC00909 in the RNA level (Fig. S4A). Similarly, in the clinical specimens we collected, we also observed that MERC2, ZNF839, and LASP1 exhibited a moderated correlation with LINC00909 at the RNA level. Meanwhile, our findings revealed that MRC2, LASP1, and ZNF839 were upregulated in ovarian cancers, especially in the subtype of serous ovarian cancer (Fig. S4B). Besides, our real-time qPCR results suggested that, in LINC00909-overexpressed OVCAR4 cells, the mRNA level of MRC2, ZNF839, and LASP1 were substantially elevated (Figure 1(f)). However, these effects were largely blocked by knocking down miR-23b-3p expression by miRNA inhibitor (Figure 1(f) and S4C). Altogether, our findings demonstrated that LINC00909 is a ceRNA of MRC2, LASP1, and ZNF839 mRNA in the mediation of miR-23b-3p in ovarian cancer cells.

3.7. LINC00909 Achieves Its Biological Functions in Ovarian Cancer via Regulating MRC2

Furthermore, we knocked down the expression of MRC2, LASP1, and ZNF839 using shRNA construct in SKOV3 cells (Figure 7(a)). Intriguingly, our data showed that only knockdown of MRC2 expression in SKOV3 significantly decreased about 61.3% of colony formation (Figure 7(b)). Meanwhile, we also overexpressed the expression of MRC2, LASP1, and ZNF839 in OVCAR4 cells (Figure 7(c)). Consistently, the colony formation assay results revealed that ectopic MRC2 efficiently increased colony formation in OVCAR4 cells (Figure 7(d)). These findings demonstrated that only MRC2 (but not LASP1 and ZNF839) exhibits oncogenic roles in ovarian cancer cells in vitro. To further investigate the relation between LINC00909 and MRC2 in ovarian cancer cells, we overexpressed LINC00909 in MRC2 knockdown OVCAR4 cells (Fig. S5A). In the colony formation assay, we found that the increased colony formation induced by LINC00909 overexpression was obviously blocked after knocking down the expression of MRC2 in OVCAR4 cells (Figure 7(e)). Similarly, downregulation of MRC2 in OVCAR4 cells also largely reduced the tumorsphere formation enhanced by LINC00909 overexpression (Figure 7(f)). These data definitely indicated that MRC2 mediates LINC00909’s oncogenic roles in ovarian cancer cells. Previously, MRC2 has been proved to participate in the process of EMT associated with cancer progression by disrupting epithelial cell-cell interactions [35, 36]. In our experiments, we found that the EMT induced by overexpression of LINC00909 in OVCAR4 cells also was remarkably blocked by knockdown of MRC2 expression, indicated by the alteration of E-cadherin/N-cadherin/vimentin protein level in Figure 7(g). Therefore, our observations collectively demonstrated that LINC00909 achieves oncogenic functions in ovarian cancer cells via regulating MRC2.

4. Discussion

Over the past decade, a large number of IncRNAs (more than 13000 according to the GENCODE project) have been identified due to the advances in next-generation RNA sequencing and bioinformatics analysis technologies [17–19]. Accumulating studies have demonstrated that IncRNA is implicated in a variety of biological processes and is closely associated with tumor development [13, 15, 18, 19, 27, 37, 38]. IncRNAs also show finite potential in clinical molecular diagnosis in various types of cancers [18, 19]. For example, a clinical investigation by Martini et al. revealed that patients with stage I epithelial ovarian cancer can be clearly stratified into low- and high-risk individuals using the expression profile IncRNAs including PVT1, SERTAD2-3, and miR-200c-3p simultaneously [39].

In the present study, after determining more than 68 IncRNA expression, we found that LINC00909, a long intergenic noncoding RNA, was upregulated in both tumor and serum of patients with OC (including serous, endometrioid, and clear-cell ovarian carcinomas) when compared with that in normal ovarian tissue. Furthermore, the tumor LINC00909 level is positively correlated with that in serum, but whether there is a causality remains further investigation. Moreover, in ROC analysis using LINC00909 level (median as the cutoff), we found the tumor and serum LINC00909 can distinguish OCs from normal ovarian tissues with an AUC of 79.0% (73.1%-85.0%) and 81.2% (76.3%-86.2%), respectively, and show a slightly but significantly better performance in identifying serous ovarian carcinoma from normal ovarian tissues. Also, we demonstrated that the cancer FIGO stages and ECOG score (reflecting patient performance status) positively associated with LINC00909 expression. However, we found that neither tumor nor serum LINC00909 discriminates advanced-stage OC (FIGO stage-III/IV) from early-stage ones (FIGO stage-I/II) (data not shown). The possible explanation is that the number of patients with advanced-stage OC is too small. Furthermore, we noticed that the tumor and serum LINC00909 exhibit a moderate correlation in their expression level, implying the serum LINC00909 may originate from tumor cells. However, our results also showed that quite considerable patients’ serum LINC00909 at the point of one-week postprimary surgery significantly elevated when compared to that of pri-diagnosis. After checking the operation efficiency of 83 patients followed up (roughly divided into the total and partial resection groups), we failed to observe a distinguishable difference in serum LINC00909 level between the complete-resection and partial-resection groups (data not shown) at the point of one-week postprimary surgery. We consider that the superficial contradiction may be caused
Cytoreductive (debulking) surgery and platinum-based chemotherapy are the initial treatment for patients with OC [3, 39]. Different lines of evidence have revealed that lncRNAs are implicated in platinum-resistant ovarian cancers. For example, in recurrent platinum-resistant ovarian tumors, HOTAIR expression was elevated, which contributes to the platinum resistance of OC [40]. In our experiments, we observed that the serum LINC00909 level was downregulated after surgical operation and platinum-based chemotherapy. The phenomenon may be based on two reasons: (1) the serum LINC00909 is derived from ovarian cancer cells (such as tumor-derived exosomes) and (2) interventions cause a substantial reduction in cancer cells. Nevertheless, we failed to observe a distinguishable difference in tumor LINC00909 level between chemotherapy-sensitive and chemotherapy-resistant patients with ovarian cancer. Thus, whether LINC00909 is implicated in the mechanisms of platinum-based chemotherapy resistance needs further investigation.

Furthermore, our results of overall and progression-free (PFS) survival analyses using LINC00909 level showed that low tissue and serum LINC00909 are favorable for the patients with ovarian cancers, corroborated by the relative longer overall and progression-free survivals in patients with low LINC00909 level. In biological functions, we demonstrated that loss-function of LINC00909 in SKOV3 cells (a LINC00909-high ovarian cancer cell line) restrained cell proliferation, migration and invasion, and in contrast, over-expression in OVCAR4 cells (a LINC00909-low ovarian cancer cell line) promoted cell migration and invasion. Likewise, the elevation of LINC00909 expression also was observed in glioma tissues and cell lines, which enhances glioma cell proliferation, invasion in vitro, and reduced tumor growth in vivo [41]. More recently, Ma et al. reported that LINC00909 was distinctly upregulated in AML patients and cell lines, and knockdown of LINC00909 suppressed cell viability, migration, and invasion [42]. In molecular mechanism, we identified miR-23b-3p as a downstream functional mediator from 33 putative miRNA interactors based on the following findings: (1) dual-luciferase showed that LINC00909 directly interacts with miR-23b-3p, (2) ectopic miR-23b-3p in SKOV3 cells inhibits colony formation, and (3) overexpression of LINC00909 overcomes miR-23b-3p’s tumor suppressor effect in OVCAR4 cells. Besides, our observations showed that LINC00909 functions as a ceRNA of MRC2 mRNA by sponging miR-23b-3p. Overexpression of MRC2 in SKOV3 cells efficiently inhibits their colony formation ability. However, LINC00909 in human glioma directly interacts with miR-194 in Liu’s study, whereas LINC00909 promotes cell proliferation and metastasis in pediatric acute myeloid leukemia via miR-625-5p [41, 42]. In our results, we also observed that miR-194-5p and miR-625-5p directly interact with LINC00909 in the dual-luciferase assay. Nevertheless, the expression level of miR-625-5p is extremely low in ovarian tissues, which restricts its regulatory potential in the tumorigenesis of ovarian cancer. Although knockdown of miR-194-5p in SKOV3 cells also profoundly inhibited colony formation, overexpression of LINC00909 failed to overcome the effects (colony formation) of ectopic miR-194-5p in SKOV3. Therefore, we consider that miR-23b-3p is a critical functional mediator of LINC00909 in the background of ovarian cancer cells. Meanwhile, the loss-function of MRC2 in OVCAR4 cells also largely blocked the EMT process induced by LINC00909 overexpression. In fact, the elevation of MRC2 protein level has been frequently observed in multiple cancer types, including breast and prostate tumors [36, 43]. Also, MRC2 contributes to the EMT process associated with cancer progression by disrupting epithelial cell-cell interactions [36, 43]. These observations are consistent with our results related to MRC2’s functional assay. Therefore, we consider that LINC00909 executes its oncogenic functions, such as promoting cancer cell proliferation, migration, and invasion, by influencing MRC2 expression.

In summary, we demonstrated that the expression of LINC00909 is elevated in the tumor and serum of patients with ovarian cancers including serous, endometrioid, and clear-cell ovarian carcinomas. Serum LINC00909 is effective in diagnosing epithelial ovarian cancers or serous ovarian carcinoma from normal ovarian tissue. High serum LINC00909 level predicts a poor prognosis (including overall and progression-free survival) for OC patients. In mechanism, the elevated LINC00909 level in ovarian cancer cells upregulates the expression of MRC2 by sponging miR-23b-3p, and thereby promotes cell proliferation, migration, invasion, and EMT of ovarian cancer cells (Figure 7(h)). Therefore, we highlight that the LINC00909/miR-23b-3p/MRC2 axis is implicated in the pathogenesis of ovarian cancer, and serum LINC00909 may be a promising biomarker for the diagnosis of OC.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

XY and KJL did the study design. GXW, FY, LH, XHX, LL, LY, YLM, QQ, JC, SYZ, QH, YW, SL, JL and BH performed experiments and collected the data. FY performed the data analysis and interpretation. FY and XY wrote the manuscript. Xu Yang, Guixia Wu, and Fan Yang contributed equally to this work. Xu Yang (Lead Contact).

Supplementary Materials

Figure S1: LINC00909 expression is elevated in tumors and serum of OC patients. (a) The level of lncRNAs was determined by real-time qPCR. Tissues of normal ovarian
(N = 89), serous (N = 170), endometrioid (N = 25), and 22
clear-cell ovarian cancer (N = 22) were used for lncRNA rel-
ative quantification. (b) The level of serum LINC00909
among different FIGO stages was determined by droplet dig-
tal PCR. Tissues of normal ovarian (N = 89), serous
(N = 170), endometrioid (N = 25), and 22 clear-cell ovarian
cancer (N = 22) were used for lncRNAs quantification. (c)
The level of serum LINC00909 among patients with different
ECOG scores was determined by droplet digital PCR. Tissues
of normal ovarian (N = 89), serous (N = 170), endometrioid
(N = 25), and 22 clear-cell ovarian cancer (N = 22) were used
for lncRNA quantification. Figure S2: LINC00909 is essential
for the migration and ovarian carcinoma cells. (A–C) The
level of LINC00909 was determined by real-time qPCR. In
(B), * indicates SKOV3 cell lines which were stably tranc-
sected with independent shRNA vector. In (C), LINC00909
was stably transfected into OVCAR4 cells (N = 4). (a) MTT
test indicated cell proliferation of OVCAR4 cells. Cells in
S2C were used. (E, F) Colony formation (E) and soft agar
(F) assays revealed the tumor characteristics of each
OVCAR4 cell line. Cells in S2C were used. (G) Wound-
healing assay determined the migration of OVCAR4. Cells
in S2C were used. *Comparisons with day 2 of scramble
group; ‡comparisons with day 3 of the scramble group. (H)
Western blot showed the protein level of EMT markers in
OVCAR4 cells. Cells in S2C were used. E-cadherin, epithelial
marker; N-cadherin/Vimentin, mesenchymal marker. Figure
S3: miR-23b is a critical functional mediator of LINC00909.
(a) The expression and subcellular location of LINC00909
data in different cell lines are from the lncATLAS database.
DANCR serves as a cytoplasmic lncRNA marker; MEAT as a
nuclear lncRNA marker. Relative concentration index (RCI).
C: cytoplasmic; N: nuclear. (b) The level of indicated miRNAs
was determined by real-time qPCR. SKOV3 cells were stably
transfected with the indicated miRNAs. Figure S4: LINC00909
functions as a ceRNA by sponging miR-23b in ovarian cancer
cells. (a) Scatter plot showed the correlation between
LINC00909 and MRC2/ZNF839/DEPC1/LASP1 mRNA.
GAPDH serves as a negative control. Data were collected from
the GEPIA database. R: Pearson correlation coefficient. (b) The
mRNA level of indicated genes was determined by real-time
qPCR. Tissues of normal ovarian (N = 89), serous (N = 170),
endometrioid (N = 25), and 22 cell ovarian cancer (N = 22)
were used for expression level quantification. (c) The level of
miR-23b-3p in OVCAR4 cells was determined by real-time
qPCR. LINC00909 was stably transfected, and miR-23b-3p
inhibitor was transiently transfected. Figure S5: LINC00909
achieves its biological functions in ovarian cancer via regulat-
ing MRC2. (a) The MRC2/LINC00909 level in OVCAR4 cells
was determined by real-time qPCR. In OVCAR4 cells, LINC00909
was stably overexpressed, and MRC2 was stably knocked down
using an shRNA vector. (Supplementary Materials)

References
[1] S. Javadi, D. M. Ganeshan, A. Qayyum, R. B. Iyer, and
P. Bhosale, “Ovarian cancer, the revised FIGO staging system,
and the role of imaging,” AJR. American Journal of Roentgen-
ology, vol. 206, no. 6, pp. 1351–1360, 2016.
[2] H. D. Reavis and R. Drapkin, “The tubal epigenome - an
emerging target for ovarian cancer,” Pharmacology & Thera-
peutics, vol. 210, p. 107524, 2020.
[3] R. Arend, A. Martinez, T. Szul, and M. J. Birrer, “Biomarkers in
ovarian cancer: to be or not to be,” Cancer, vol. 125, Suppl 24,
p. 4563–4572, 2019.
[4] G. C. Jayson, E. C. Kohn, H. C. Kitchener, and J. A. Leder-
mann, “Ovarian cancer,” The Lancet, vol. 384, no. 9951,
pp. 1376–1388, 2014.
[5] D. G. Mutch and J. Prat, “2014 FIGO staging for ovarian, fal-
lopian tube and peritoneal cancer,” Gynecologic Oncology,
vol. 133, no. 3, pp. 401–404, 2014.
[6] K. R. Cho and I. M. Shih, “Ovarian cancer,” Annual Review of
Pathology, vol. 4, no. 1, pp. 287–313, 2009.
[7] M. R. Mirza, R. L. Coleman, A. Gonzalez-Martín et al., “The
forefront of ovarian cancer therapy: update on PARP inhibi-
tors,” Annals of Oncology, vol. 31, no. 9, pp. 1148–1159, 2020.
[8] N. Gil and I. Ulitsky, “Regulation of gene expression by _cis_
-acting long non-coding RNAs,” Nature Reviews. Genetics,
vol. 21, no. 2, pp. 102–117, 2020.
[9] L. Cui, X. Y. Xie, H. Wang, X. L. Chen, S. L. Liu, and L. N. Hu,
“Expression of long non-coding RNA HOTAIR mRNA in
ovarian cancer,” Sichuan Da Xue Xue Bao Yi Xue Ban, vol. 44,
n. 1, pp. 57–59, 2013.
[10] Y. Peng, D. Tang, M. Zhao, H. Kajiyama, F. Kidkawa, and
Y. Kondo, “Long non-coding RNA: A recently accentuated
molecule in chemoresistance in cancer,” Cancer Metastasis
Reviews, vol. 39, no. 3, pp. 825–835, 2020.
[11] A. Bhan, M. Soleimani, and S. S. Mandal, “Long noncoding
RNA and cancer: a new paradigm,” Cancer Research, vol. 77,
n. 15, pp. 3965–3981, 2017.
[12] A. Sanchez Calle, Y. Kawamura, Y. Yamamoto, F. Takeshita,
and T. Ochiya, “Emerging roles of long non-coding RNA in
cancer,” Cancer Science, vol. 109, no. 7, pp. 2093–2100, 2018.
[13] A. M. Schmitt and H. Y. Chang, “Long noncoding RNAs in
cancer pathways,” Cancer Cell, vol. 29, no. 4, pp. 452–463,
2016.
[14] J. B. Moore and S. Uchida, “Functional characterization of
long noncoding RNAs,” Current Opinion in Cardiology,
vol. 35, no. 3, pp. 199–206, 2020.
[15] M. K. Tripathi, K. Doxtater, F. Keramatnia et al., “Role of
lncRNAs in ovarian cancer: defining new biomarkers for ther-
apeutic purposes,” Drug Discovery Today, vol. 23, no. 9,
pp. 1635–1643, 2018.
[16] Z. Huang, J. K. Zhou, Y. Peng, W. He, and C. Huang, “The
role of long noncoding RNAs in hepatocellular carcinoma,”
Molecular Cancer, vol. 19, no. 1, p. 77, 2020.
[17] J. J. Chan and Y. Tay, “Noncoding RNA:RNA regulatory
networks in cancer,” International Journal of Molecular Sciences,
vol. 19, no. 5, article 1310, 2018.
[18] Y. Chi, D. Wang, J. Wang, W. Yu, and J. Yang, “Long non-
coding RNA in the pathogenesis of cancers,” Cell, vol. 8,
n. 9, article 1015, 2019.
[19] Y. Fang and M. J. Fullwood, “Roles, functions, and mecha-
nisms of long non-coding RNAs in cancer,” Genomics, Proteo-
omics & Bioinformatics, vol. 14, no. 1, pp. 42–54, 2016.
[20] F. Kopp and J. T. Mendell, “Functional classification and
experimental dissection of long noncoding RNAs,” Cell,
vol. 172, no. 3, pp. 393–407, 2018.
[21] S. Chen, D. D. Wu, X. B. Sang et al., “The lncRNA HULC func-
tions as an oncogene by targeting ATG7 and ITGB1 in

Oxidative Medicine and Cellular Longevity
epithelial ovarian carcinoma,” Cell Death & Disease, vol. 8, no. 10, article e3118, 2017.

[22] H. Wang, L. Fang, J. Jiang et al., “The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation,” Cell Death & Disease, vol. 9, no. 11, p. 1103, 2018.

[23] H. Yousefi, M. Maheronnaghsb, F. Molaei et al., “Long non-coding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance,” Oncogene, vol. 39, no. 5, pp. 953–974, 2020.

[24] R. Choudhari, M. J. Sedano, A. L. Harrison et al., “Long non-coding RNAs in cancer: from discovery to therapeutic targets,” Advances in Clinical Chemistry, vol. 95, pp. 105–147, 2020.

[25] A. Misawa, K. I. Takayama, and S. Inoue, “Long non-coding RNAs and prostate cancer,” Cancer Science, vol. 108, no. 11, pp. 2107–2114, 2017.

[26] W. X. Peng, P. Koirala, and Y. Y. Mo, “LncRNA-mediated regulation of cell signaling in cancer,” Oncogene, vol. 36, no. 41, pp. 5661–5667, 2017.

[27] J. Zhang, T. D. le, L. Liu, and J. Li, “Inferring and analyzing module-specific lncRNA-miRNA causal regulatory networks in human cancer,” Briefings in Bioinformatics, vol. 20, no. 4, pp. 1403–1419, 2019.

[28] H. Liang, T. Yu, Y. Han et al., “LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression,” Molecular Cancer, vol. 17, no. 1, p. 138, 2017.

[29] D. D. Wu, X. Chen, K. X. Sun, L. L. Wang, S. Chen, and Y. Zhao, “Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC,” Molecular Cancer, vol. 16, no. 1, p. 138, 2017.

[30] F. Azam, M. F. Latif, A. Farooq et al., “Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals,” Case Reports in Oncology, vol. 12, no. 3, pp. 728–736, 2019.

[31] J.-H. Li, S. Liu, H. Zhou, L. H. Qu, and J. H. Yang, “starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data,” Nucleic Acids Research, vol. 42, no. D1, pp. D92–D97, 2014.

[32] Y. P. Hu, Y. P. Jin, X. S. Wu et al., “LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis,” Molecular Cancer, vol. 18, no. 1, p. 167, 2019.

[33] Y. Wang, L. Yang, T. Chen et al., “A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis,” Molecular Cancer, vol. 18, no. 1, p. 28, 2019.

[34] Y. Liang, X. Song, Y. Li et al., “LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis,” Molecular Cancer, vol. 19, no. 1, p. 85, 2020.

[35] J. Sturge, D. Wienke, and C. M. Isacke, “Endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly,” The Journal of Cell Biology, vol. 175, no. 2, pp. 337–347, 2006.

[36] D. Wienke, G. C. Davies, D. A. Johnson et al., “The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo,” Cancer Research, vol. 67, no. 21, pp. 10230–10240, 2007.